The ovarian cancer patients with chemotherapy showed less myelosuppression (neutrophil count less than 1.5 G/L) in the postlockdown cohort (16/47, 34.0%) compared to the prelockdown cohort (52/102, 51.0%) and the 2019 cohort (41/95, 43.2%), which may be due to the more frequent use of long‐term treatment with colony stimulating factor (PEG‐rhG‐CSF). The gene discussed is CSF2; the disease is ovarian cancer.